Drug Profile


Alternative Names: Dental pulp stem cells - JCR; DPCs-JCR; JR-161

Latest Information Update: 25 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator JCR Pharmaceuticals
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cerebral infarction

Most Recent Events

  • 18 Jul 2017 JCR Pharmaceuticals plans clinical development for Cerebral infarction in Japan in 2018
  • 18 Jul 2017 JCR Pharmaceuticals and Teijin agree to co-promote and co-develop JTR-161 in Japan for Cerebral infraction
  • 18 Jul 2017 Preclinical trials in Cerebral infarction in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top